AptarGroup, Inc. (ATR)
| Market Cap | 8.04B |
| Revenue (ttm) | 3.78B |
| Net Income (ttm) | 392.79M |
| Shares Out | 63.77M |
| EPS (ttm) | 5.89 |
| PE Ratio | 21.40 |
| Forward PE | 22.81 |
| Dividend | $1.92 (1.52%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 269,902 |
| Open | 125.00 |
| Previous Close | 124.73 |
| Day's Range | 124.58 - 126.12 |
| 52-Week Range | 103.23 - 164.28 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 170.25 (+35.09%) |
| Earnings Date | Apr 30, 2026 |
About ATR
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations,... [Read more]
Financial Performance
In 2025, AptarGroup's revenue was $3.78 billion, an increase of 5.42% compared to the previous year's $3.58 billion. Earnings were $392.79 million, an increase of 4.87%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ATR stock is "Buy." The 12-month stock price target is $170.25, which is an increase of 35.09% from the latest price.
News
Aptar Declares Quarterly Dividend
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Declares Quarterly Dividend.
Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution
CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (“Enable”), a healthcare ...
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces Gael Touya as its Next President and Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year.
AptarGroup Transcript: 47th Annual Raymond James Institutional Investor Conference
A global leader in drug and consumer product dispensing, the company reported $3.8 billion in 2025 revenue, with pharma as its core growth engine. Strong innovation, a diversified pipeline, and sustainability leadership support long-term growth, with margin improvements expected across all segments in 2026.
AptarGroup Transcript: Bank of America 2026 Global Agriculture and Materials Conference
Proprietary drug delivery systems are expanding into new therapeutic areas, with strong growth in injectables and consumer businesses. Operational improvements and regional strategies, especially in China, support resilience. Margin expansion is expected as capacity investments and product mix evolve.
Top 3 Materials Stocks That May Plunge This Month
As of Feb. 23, 2026, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Aptar to Participate in Upcoming Investor Conferences
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences.
AptarGroup Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong sales growth and robust innovation, with all segments delivering core sales gains. Margins were pressured by mix and operational issues, but sequential improvement is expected in 2026. Emergency medicine remains a headwind, but pharma, beauty, and closures show positive momentum.
Aptar Reports Fourth Quarter and Annual 2025 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports Fourth Quarter and Annual 2025 Results.
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details.
Aptar Again Recognized with Prestigious ‘A' Score on the CDP Climate Change Assessment
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Again Recognized with Prestigious ‘A' Score on the CDP Climate Change Assessment.
AptarGroup Transcript: 44th Annual J.P. Morgan Healthcare Conference
Pharma leads with proprietary drug delivery and robust IP, driving two-thirds of EBITDA and a strong, expanding pipeline. Capital allocation remains balanced, with high investment in growth and record share buybacks. Nasal and injectable innovations, digital health partnerships, and global expansion underpin future growth.
Aptar Announces 2026 Quarterly Conference Call Dates
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces 2026 Quarterly Conference Call Dates.
Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) L...
Aptar Named One of America's Most Responsible Companies by Newsweek for the Seventh Consecutive Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America's Most Responsible Companies by Newsweek for the Seventh Consecutive Year.
Aptar Strengthens Latin America Footprint With Sommaplast Buy
On Monday, AptarGroup, Inc. (NYSE: ATR) acquired Sommaplast, a specialized provider of oral dosing pharma packaging solutions, such as closures, droppers, dispensers, and dosing cups, based in Brazil.
AptarGroup Transcript: Jefferies London Healthcare Conference 2025
Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025.
AptarGroup Earnings Call Transcript: Q3 2025
Q3 saw adjusted EPS of $1.62, with pharma growth in injectables and drug delivery, offset by consumer healthcare destocking. Emergency medicine faces a 35% revenue decline in 2026, compressing margins, but long-term pharma growth targets remain intact.
Aptar Reports Third Quarter 2025 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports Third Quarter 2025 Results.
AptarGroup Transcript: Investor Day 2025
Raised ROIC and maintained strong growth and margin targets, supported by innovation in Pharma, Beauty, and Closures. Operational efficiency and disciplined capital allocation drive profitability, with free cash flow and shareholder returns set to grow further.
Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength.
Aptar Announces 2025 Investor Day
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces 2025 Investor Day.
AptarGroup Earnings Call Transcript: Q2 2025
Q2 results exceeded guidance with 18% EPS growth and strong performance across all segments, led by Pharma and Closures. Outlook for Q3 is cautious due to naloxone normalization, legal expenses, and ongoing European inventory headwinds, but innovation and capital returns remain robust.